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“At a Glance Commentary” 
 
What is the current scientific knowledge on this subject? 
Rifapentine has become a principle component of novel short-course regimens for latent 
tuberculosis infection and a promising agent for treatment shortening regimens for active 
disease. Evidence suggests that rifapentine induces its own elimination, but the implications for 
novel dosing strategies are not well understood. Further, the evidence supporting the current 
weight band dosing of rifapentine is lacking and requires further evaluation. 
 
What does this study add to the field? 
In this individual participant data meta-analysis of rifapentine pharmacokinetics, we describe the 
population pharmacokinetics of rifapentine, including full characterization of the autoinduction 
profile. We find no evidence supporting weight band dosing of rifapentine and thus, recommend 
all individuals receive the same dose, with the exception of HIV-positive individuals, who would 
benefit from higher doses. This model will serve as a valuable tool for predicting drug exposure 
and determining optimal rifapentine doses for future clinical trials and in clinical practice. 
 
 
  
 1 
Abstract 1 
 2 
Rationale: Rifapentine has been investigated at various doses, frequencies, and dosing 3 
algorithms but clarity on the optimal dosing approach is lacking. 4 
Objectives: In this individual participant data meta-analysis of rifapentine pharmacokinetics, we 5 
characterize rifapentine population pharmacokinetics, including autoinduction, and determine 6 
optimal dosing strategies for short-course rifapentine-based regimens for latent tuberculosis 7 
infection. 8 
Methods: Rifapentine pharmacokinetic studies were identified though a systematic review of 9 
literature. Individual plasma concentrations were pooled, and non-linear mixed effects modeling 10 
was performed. A subset of data was reserved for external validation. Simulations were 11 
performed under various dosing conditions including current weight-based methods and 12 
alternative methods driven by identified covariates.  13 
Measurements and Main Results: We identified 9 clinical studies with a total of 863 14 
participants with pharmacokinetic data (n=4301 plasma samples). Rifapentine population 15 
pharmacokinetics were described successfully with a one-compartment distribution model. 16 
Autoinduction of clearance was driven by rifapentine plasma concentration. The maximum effect 17 
was a 72% increase in clearance and was reached after 21 days. Drug bioavailability decreased 18 
by 27% with HIV infection, decreased by 28% with fasting, and increased by 49% with a high-19 
fat meal. Body weight was not a clinically relevant predictor of clearance. Pharmacokinetic 20 
simulations showed that current weight-based dosing leads to lower exposures in low weight 21 
individuals, which can be overcome with flat dosing. In HIV-positive patients, 30% higher doses 22 
are required to match drug exposure in HIV-negative patients. 23 
 2 
Conclusions: Weight-based dosing of rifapentine should be removed from clinical guidelines 24 
and higher doses for HIV-positive patients should be considered to provide equivalent efficacy.  25 
 26 
Abstract word count: 250/250 27 
 28 
Keywords: tuberculosis; rifapentine; rifamycins; population pharmacokinetics; latent 29 
tuberculosis  30 
 3 
Introduction 31 
The World Health Organization (WHO) estimates that 23% of the world’s population has latent 32 
tuberculosis infection (LTBI) and is at risk of developing active disease (1). Standard treatment 33 
for LTBI has historically been 9 months of daily isoniazid, for which patient compliance is poor 34 
and hepatotoxicity is a concern (2, 3). Recently, novel rifapentine-based regimens have 35 
demonstrated efficacy in preventing tuberculosis disease with much shorter treatment durations. 36 
(4, 5). Additionally, these regimens have shown equal to better safety profiles and higher patient 37 
compliance. The first regimen was three months of once-weekly rifapentine plus isoniazid (3HP) 38 
(4); it received FDA approval in 2014 and is now recommended by the Centers for Disease 39 
Control and the WHO for individuals with LTBI (6-8). An ultra-short-course regimen, one 40 
month of daily isoniazid-rifapentine (1HP), has also shown efficacy, safety, and improved 41 
compliance in HIV-infected patients at high risk of developing tuberculosis disease (5); 1HP 42 
inclusion into WHO guidelines is under review (9).  43 
 44 
Rifapentine has high anti-mycobacterial activity and a long elimination half-life of 15 hours that 45 
makes it an attractive candidate for treatment shortening regimens (6, 10, 11). However, unlike 46 
in LTBI, it is still unknown if rifapentine will be effective in short-course regimens for active 47 
drug-sensitive tuberculosis disease (DS-TB). The only completed Phase 3 clinical trial (Rifaquin) 48 
failed to demonstrate non-inferiority of intermittent rifapentine regimens in DS-TB patients 49 
compared to the 6-month standard of care (12). 50 
 51 
Robust characterization of rifapentine pharmacokinetics is required to determine optimal dosing 52 
strategies for new short-course regimens and for special populations. Current rifapentine-based 53 
 4 
regimens for LTBI use weight band dosing (6, 8). However, these recommendations are not 54 
based on pharmacokinetic evidence; rather, they are drawn from the historical mg/kg doses used 55 
in rifampin-based therapy. The influence of body weight on rifapentine clearance remains 56 
inconclusive as current studies report conflicting findings (13, 14). Meal-type, dose amount, HIV 57 
status, race, and age may also impact rifapentine concentration (14-18). Additionally, repeated 58 
dosing of twice weekly and daily administration results in lower rifapentine exposures over time, 59 
suggesting that rifapentine induces its own metabolism (19, 20).  60 
 61 
Several Pharmacokinetic studies have been conducted with varying rifapentine doses (up to 20 62 
mg/kg daily), frequencies (once weekly to twice daily), and methods (weight-based or flat dose) 63 
(19-22). Our aim here was to perform an individual participant data meta-analysis and pool 64 
individual pharmacokinetic data from all relevant clinical studies in various populations (healthy 65 
volunteers and LTBI and DS-TB patients with and without HIV infection). The goals are (i) to 66 
characterize rifapentine population pharmacokinetics, including the time course of autoinduction 67 
and relevant covariates that may have a significant clinical impact on rifapentine exposures and 68 
clinical efficacy, and (ii) to derive dosing recommendations to inform optimal current and future 69 
use of rifapentine in tuberculosis infection and disease. 70 
 71 
Methods 72 
Clinical Studies 73 
Rifapentine pharmacokinetic studies were identified through a literature search in PubMed with 74 
the terms ‘rifapentine’ AND (‘study’ OR ‘trial’) from 1 January 1980 to 31 December 2015 75 
according to PRISMA guidelines (23). Additional studies were identified through author 76 
 5 
collaborations. Corresponding authors of the study were invited to contribute data if the studies 77 
were prospective and multiple dose, pharmacokinetic measurements were available and 78 
validated, and covariates of interest were documented (e.g., HIV status, meal-type, and weight). 79 
All studies included in the analysis received ethical approval by their local ethical review boards.  80 
 81 
Population Pharmacokinetic Analysis 82 
Identified studies were split into an analysis cohort for structural model development and a 83 
validation cohort for external validation. We sought to conserve 1/3 of drug concentration data 84 
for the validation cohort and to match dosing schedules and covariates (eg, HIV) between 85 
cohorts when possible. Rifapentine plasma concentrations were natural log-transformed and 86 
analyzed using non-linear mixed effects modeling with NONMEM 7.41 (ICON Development 87 
Solutions, Elliott City, Maryland). Pharmacokinetic data without an associated dosing record 88 
were excluded.  89 
 90 
Population pharmacokinetic model building followed standard procedures by first characterizing 91 
the base structural model (24). To describe rifapentine autoinduction, a semi-mechanistic 92 
enzyme turnover model was used (25). Known covariate effects (i.e., HIV, meal-type, dose) 93 
were incorporated into the structural model. Additional covariate effects such as weight, age, 94 
race, BMI and sex were identified through a stepwise procedure with forward selection (p<0.05) 95 
and backward elimination (p<0.01). Final inclusion of covariates was based on statistical 96 
significance, scientific plausibility, and clinical relevance defined as > 20% change in the 97 
parameter estimate (26). Model development was guided by graphical assessment of goodness-98 
of-fit plots, condition number, and the likelihood ratio test. Simulation-based diagnostics (e.g., 99 
 6 
visual predictive check [VPC]) were used for model validation. Detailed model building 100 
procedures are provided in the Supplemental material.  101 
 102 
Software 103 
R software (version 3.4.2) was used for all data management, analyses, and graphical 104 
visualization. The xpose (version 0.4.4) and vpc (version 1.0.1) packages were used for visual 105 
diagnostics. Nonparametric bootstrap and covariate modeling were performed with Perl-speaks-106 
NONMEM (version 4.7.0). 107 
 108 
Dosing simulations 109 
Simulations were performed with the final model to (i) predict the autoinduction process with 110 
different doses and dosing schedules, (ii) assess the impact of clinically relevant patient factors 111 
(e.g., HIV, weight) on rifapentine exposure, and (iii) to propose pragmatic dosing for rifapentine-112 
containing LTBI regimens. Pharmacokinetic profiles were evaluated by different drivers of 113 
pharmacodynamics, including time above minimum inhibitory concentration (MIC), area under 114 
the concentration-time curve (AUC), AUC/MIC, maximum concentration (Cmax), and Cmax/MIC, 115 
with MIC set to 0.06 mg/L (27). For 1HP and 3HP simulations, we predicted rifapentine 116 
exposure following current weight band dosing (1HP: 300 mg [<35 kg], 450 mg [35-45 kg], or 117 
600 mg [>45 kg] daily; 3HP: 750 mg [<50 kg] and 900 mg [>50 kg] once weekly) (4, 5). 118 
Alternative dosing methods were explored based on identified covariates. All simulations were 119 
performed under low-fat meal conditions (the referent, where relative bioavailability =1) given 120 
label recommendations. 121 
 122 
 7 
Univariate analysis of month 2 culture conversion 123 
Microbiological outcome data (i.e., liquid and solid culture data) was acquired from two Phase II 124 
clinical studies: TBTC-29 and TBTC-29x (22, 28). Participant body weight and rifapentine AUC 125 
were evaluated as predictors month 2 culture conversion by logistic regression. Body weight was 126 
categorized as < 50 kg or > 50 kg, consistent with the weight band dosing strategy used in these 127 
studies. AUC was categorized at the median AUC.  128 
 129 
 130 
Results 131 
Clinical Studies 132 
We identified nine clinical studies with rifapentine pharmacokinetic data for the pooled analysis 133 
(Figure 1), including Phase 3 (n=2), Phase 2 (n=4), and Phase 1 (n=3) studies (12, 14, 19-21, 28-134 
31). Overall, 863 subjects were included: 84 healthy volunteers, 702 patients with DS-TB, and 135 
77 persons treated for LTBI. The analysis cohort included 360 subjects (n=3273 samples) from 136 
five studies. The validation cohort included 503 subjects (n=1115 samples) from four studies. 137 
Participant and trial characteristics are shown in Table 1. The analysis and validation cohorts 138 
were similar in design and participant characteristics. Overall, the median age was 34 years, the 139 
median weight was 59 kg, 31% were men, and 9% of patients were HIV-positive. There was a 140 
wide range of rifapentine doses, dosing frequencies, and diets that were tested across studies 141 
(Table 1).  142 
 143 
Pharmacokinetic-enzyme model 144 
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The final rifapentine pharmacokinetic-enzyme model is shown in Figure 2, and final parameter 145 
estimates are in Table 2. All pharmacokinetic parameters were well estimated with low relative 146 
standard errors. Rifapentine apparent clearance was estimated to be 1.11 L/h in the typical adult 147 
and increased up to 1.92 L/h (173%) over time as a result of autoinduction. The induction 148 
process was described using an indirect response semi-mechanistic enzyme turnover model 149 
(Figure 2). The effect (EFF) of rifapentine drug concentration on enzyme production was 150 
described through an Emax relationship: 151 
EFF = $	 E!"# ∙ 	C$	%EC&'	% +	C$	%) 152 
where EC50 is the rifapentine concentration in plasma (Cp) when half the maximum induction 153 
effect (Emax) is observed; g represents the steepness of the relationship. The maximum 154 
autoinduction effect is expected at the steady state concentrations achieved with daily doses of 155 
300 mg or more, and clearance stabilizes by day 21 of therapy, assuming 5 half-lives to steady 156 
state (Figure 3).  157 
 158 
Rifapentine model evaluation and validation 159 
The VPC of the basic structural model (built with analysis cohort data alone) shows that the 160 
model predicted the analysis cohort raw data well: the median, 5th, and 95th percentiles of raw 161 
data fell within or near the percentiles of model-predicted concentrations for all time points 162 
(Figure 4A). Further, we show that model-predicted concentrations matched the raw data of an 163 
external dataset (i.e., the validation cohort, which was not used in model development; Figure 164 
4B). 165 
 166 
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After model validation, data from both cohorts were pooled and parameters re-estimated. VPCs 167 
of the final pharmacokinetic model for rifapentine and its metabolite are provided in the 168 
Supplement. The final model predicted rifapentine (Figure E2) and metabolite (Figure E3) 169 
concentrations well for all studies. 170 
 171 
Impact of covariates on rifapentine pharmacokinetics 172 
Rifapentine bioavailability was strongly (p<0.001) influenced by HIV status, food, and dose with 173 
clinically relevant effect sizes. The relative effects on bioavailability of HIV-positive status (vs. 174 
HIV-negative), high-fat meal or fasting condition (vs. low-fat meal), and dose per 100 mg above 175 
300 mg (the referent) are shown in Table 2. Body weight was related to rifapentine clearance 176 
(p<0.001) with a 0.1 L/h (9%) increase in clearance per 10 kg increase in weight (Figure 5). 177 
However, weight explained only 2.9% of the inter-individual variability in clearance, and the 178 
effect size did not meet our criteria for clinical relevance. Further, the majority of statistical 179 
significance was from a few influential individuals over 90 kg in weight (Supplemental). 180 
Allometrically scaling clearance did not provide any additional improvement over the linear 181 
relationship, and the functions were nearly identical at relevant weight ranges (40-100 kg). 182 
Therefore, the only covariates included in the final model were HIV, food, and dose. 183 
 184 
Rifapentine simulations of different dosing schedules 185 
The effect of dose and dosing frequency on rifapentine pharmacokinetics is shown in Figure 6. 186 
With intermittent dosing, autoinduction was minimal to moderate and clearance increased 187 
slightly with larger doses (see Supplemental). With daily dosing, maximum induction was 188 
achieved with doses of 300 mg or more. All dosing schedules were able to maintain 189 
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concentrations above MIC during the dosing interval except once weekly in which 190 
concentrations fall below MIC just prior to the next dose (Figure 6B). Cmax/MIC and AUC/MIC 191 
were highest with daily dosing, due to drug accumulation, and increased with increasing dose 192 
(Online data supplement, E2 Table). 193 
 194 
Rifapentine simulations for 1HP and 3HP therapy  195 
We simulated rifapentine drug concentrations under the 1HP and 3HP regimens for LTBI in both 196 
HIV-positive and HIV-negative adults. The typical HIV-positive patient had lower drug 197 
concentrations than the typical HIV-negative patient when given the same dose due to decreased 198 
rifapentine bioavailability (Figure 7).  Lower drug concentrations are also predicted in low 199 
weight individuals with the current weight band dosing (Figure 7). Removing weight bands and 200 
administering the same flat dose to all individuals would result in equal exposures across 201 
weights; however, it did not equalize exposures by HIV status (Figure 8). With a stratified 202 
regimen, where HIV-positive individuals receive ~30% higher doses, similar exposures are 203 
expected by HIV status and weight for both 1HP and 3HP (Figure 8). 204 
 205 
Univariate analysis of month 2 culture conversion 206 
A total of 363 individuals treated with 10 mg/kg rifapentine had Phase II microbiological data 207 
available. Univariate logistic regression results for month 2 culture conversion of liquid media 208 
are shown in Figure 9. Month 2 culture conversion was less likely in individuals who had lower 209 
rifapentine AUC (Odds ratio = 0.49) and in those who weighed less than 50 kg (Odds ratio = 210 
0.60).  211 
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 212 
Discussion 213 
In this study, we used a pooled individual-data approach with an external validation to describe 214 
rifapentine population pharmacokinetics in a large cohort of subjects. This analysis included nine 215 
clinical studies with a wide range of rifapentine doses and scheduling frequencies, allowing for 216 
successful characterization of rifapentine autoinduction with respect to drug concentration. It 217 
represents the largest analysis of rifapentine population pharmacokinetics to date. Our results 218 
establish several findings that may help guide rifapentine dosing strategies: (i) pharmacokinetic 219 
data do not support dosing rifapentine by body weight; (ii) HIV-positive individuals require at 220 
least 30% higher doses to achieve equal drug exposures to HIV-negative persons; (iii) rifapentine 221 
autoinduction is strongly influenced by dosing frequency rather than dose amount.  222 
 223 
Since rifapentine’s approval, several studies have shown evidence of rifapentine inducing its 224 
own elimination but none have characterized autoinduction with respect to rifapentine 225 
concentration (14, 16, 17, 19, 20). Previously published models have described rifapentine 226 
autoinduction empirically with time-varying clearance model (14, 17) or reduced bioavailability 227 
(16). While these approaches are adequate for describing data, they have limited utility in clinical 228 
settings and for dose determination in new clinical trials.  In our analysis, we used a semi-229 
mechanistic turnover model where rifapentine concentration was the driver of autoinduction 230 
(25). This method is advantageous in that it allows for predicting the magnitude of autoinduction 231 
with different rifapentine regimens of various doses and frequencies, including those which have 232 
not yet been tested in a clinical trial.  233 
 234 
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Rifapentine autoinduction is strongly influenced by dosing frequency. Simulated 235 
pharmacokinetic profiles showed increasing Cmax and AUC in the first week of therapy with 236 
daily dosing due to drug accumulation but decreased thereafter as a result of clearance induction. 237 
This effect was most prominent with daily dosing, moderate with thrice weekly dosing, and 238 
minimal with less frequent dosing. These findings are in agreement with previous reports from 239 
non-compartmental analyses (20, 30, 32). Dose amount had little effect on the magnitude of 240 
autoinduction (~10% higher clearance with 1200 mg vs. 600 mg), regardless of dosing 241 
frequency. A dose effect on rifapentine autoinduction has been described previously (17, 19). In 242 
our model, nonproportional increases in drug exposure with increasing dose were described 243 
through a reduction in bioavailability, consistent with saturable absorption (14). Still, as the 244 
induction process is a function of rifapentine plasma concentration in our model, any additional 245 
dose effects on clearance would be captured. While full autoinduction is predicted with daily 246 
dosing, drug accumulation was also high, leading to superior Cmax/MIC and AUC/MIC compared 247 
to less frequent dosing. This confirms that daily dosing has the highest potential for 248 
concentration-dependent killing of M. tuberculosis. Further, this work is an important 249 
contribution to the understanding of the rifapentine dose-exposure relationship, especially in the 250 
context of DS-TB where daily dosing is likely required (15). 251 
 252 
Currently, body weight is the only dose determining factor for rifapentine, which was not 253 
supported in our analysis. In three previously described population pharmacokinetic models, 254 
weight did not influence rifapentine pharmacokinetics (15) (14, 17). Furthermore, Savic and 255 
colleagues supported flat dosing of rifapentine, which was later implemented in a Phase 3 256 
clinical trial for DS-TB (Study 31, Clinicaltrials.gov NCT02410772) (15). Contrarily, Langdon 257 
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and colleagues report a change in rifapentine clearance by 0.5 L/h per 10 kg of body weight in a 258 
small cohort of 46 patients (13). However, their model did not incorporate dose-dependent 259 
absorption (i.e., reduced bioavailability with increased dose), which likely would reduce the 260 
estimated weight effect on clearance since the study dosed by weight, and clearance and 261 
bioavailability are indirectly linked with oral dosing (13). Francis et al. allometrically scaled 262 
clearance by fat-free mass (16). The model’s application to rifapentine dosing, which is based on 263 
total body weight, was not described. Our study is the largest population pharmacokinetic study 264 
to-date with over 800 patients and healthy volunteers. While a small weight effect was observed 265 
(<10% change in clearance per 10 kg in body weight), it does not justify a 150 mg (~30%) 266 
change in dose as currently recommended in LTBI dosing guidelines. Weight and patient 267 
population appeared correlated in our dataset (i.e., DS-TB patients weighed less on average); 268 
therefore, we investigated the weight effect in healthy volunteers, individuals with LTBI, and 269 
DS-TB patients separately. The weight effect was comparable and remained clinically irrelevant. 270 
We conclude that weight is not a clinically relevant predictor of rifapentine clearance and that 271 
weight-based dosing should not be recommended.  272 
 273 
Simulations of the 1HP and 3HP regimens showed lower rifapentine exposures in low weight 274 
individuals who receive lower doses with current weight band dosing. This ultimately puts the 275 
smallest, most vulnerable individuals at risk of underexposure and consequently, treatment 276 
failure (33, 34). A univariate analysis of Phase 2 culture data from two DS-TB studies showed 277 
month 2 culture conversion was less likely in low weight individuals and those with low 278 
rifapentine exposure. While the pharmacokinetic-pharmacodynamic relationships in LTBI have 279 
not been established, rifamycins show concentration-dependent killing of M. tuberculosis and 280 
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rifapentine AUC is a strong predictor of month 2 culture conversion (15, 35). Flat dosing of 281 
rifapentine (e.g., prescribing the same dose to all adults) ensures equal rifapentine exposure in 282 
adult patients of all sizes and thus, equal chance of successful outcome. Moreover, flat dosing 283 
simplifies the regimen in adults and encourages coformulation of rifapentine and isoniazid into a 284 
fixed-dose combination tablet, reducing pill burden and simplifying the regimen even further.  285 
 286 
Dose discrimination may be warranted by HIV status. HIV-positive persons have 27% lower 287 
rifapentine bioavailability, resulting in lower exposures than HIV-negative adults. Reduced 288 
bioavailability of rifamycins with HIV infection has been reported previously (15, 17) and has 289 
been attributed to malabsorption (36-38). While antiretroviral drugs may also explain decreases 290 
in rifamycin concentration, the HIV-positive participants in our analysis did not receive 291 
antiretroviral therapy (12, 22, 28). Given rifapentine’s main metabolite has activity against M. 292 
tuberculosis, we also looked at metabolite concentrations by HIV status. It appeared that HIV-293 
positive individuals had lower exposures of both rifapentine and its metabolite, confirming need 294 
for higher doses in HIV+ patients.  Increasing the 3HP dose to 1200 mg once weekly in HIV-295 
positive patients results in similar exposures to 900 mg once weekly in HIV-negative patients. 296 
Likewise, 750 mg daily in HIV-positive adults is similar to 600 mg daily in HIV-negative adults 297 
for the 1HP regimen. While 1HP at 600 mg daily was effective in preventing tuberculosis disease 298 
in HIV-positive individuals (5), this may reflect the minimum effective dose and higher doses 299 
may provide better protection. 300 
 301 
The proposed dosing recommendations are limited by the lack of established pharmacokinetic 302 
targets in LTBI. We proposed doses that would match median exposures following the standard 303 
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doses tested in clinical trials with demonstrated efficacy. Given the development of tuberculosis 304 
was rare in those studies, these pharmacokinetic targets are reasonable, and we would expect the 305 
proposed doses to result in similar efficacy to that observed in clinical trial. The pharmacokinetic 306 
target for 1HP regimen reflects the median predicted exposure in a typical HIV-positive adult 307 
receiving 600 mg daily and may be on the low end. Pharmacokinetic data from BRIEF-TB and 308 
future trials are urgently needed to confirm pharmacokinetic thresholds for 1HP. Additionally, 309 
one study showed higher rifapentine bioavailability in Asians compared to Africans, which could 310 
impact dose requirement (15). This finding could not be confirmed in our study because TBTC 311 
29X was the only study contributing substantial Asian population. Further investigation of race 312 
effects on rifapentine pharmacokinetics is required.  313 
 314 
Our systematic review included all relevant studies published prior to 2016. Only one 315 
pharmacokinetic study was identified in more recent literature and would not have met our 316 
inclusion criteria due to non-standardized meal administration (16).  Thus, our model represents 317 
the most up-to-date analysis of rifapentine pharmacokinetics. Of note, the analysis includes only 318 
one study in LTBI participants. To-date, these remain the only pharmacokinetic data in this 319 
population. Further, there is no evidence to suggest pharmacokinetics would differ by disease 320 
state, so we do not expect this to impact the generalizability of our work to LTBI treatment. 321 
 322 
In conclusion, rifapentine exhibits autoinduction which is strongly influenced by dosing 323 
frequency. Weight was not a clinically relevant predictor of rifapentine clearance; thus, dosing 324 
should not be based on an individual’s weight. In fact, weight-based dosing results in 325 
substantially lower drug concentrations that could ultimately compromise treatment efficacy. If 326 
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stratified dosing is to be implemented, it should be done on the basis of HIV status to ensure that 327 
HIV-positive individuals are adequately exposed to drug. Lastly, as rifapentine use becomes 328 
more widespread in tuberculosis treatment and prevention, this model can serve as a useful tool 329 
in clinical practice and in clinical trial design for dose determination and exposure prediction.  330 
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Figure Legends 
 
Figure 1. PRISMA Flow Diagram. 
 
Figure 2. Final rifapentine pharmacokinetic-enzyme model. The number of transit 
compartments (NN) was estimated using the relationship of kTR = (NN+1)/MTT, where MTT is 
the mean transit time and kTR is the transit rate constant. The absorption rate constant (ka) was 
assumed equal to kTR. Rifapentine autoinduction was modeled with an enzyme turnover model, 
where the effect (EFF) of rifapentine concentration in the central compartment increased the 
enzyme production rate (kENZ), thereby increasing the enzyme pool (ENZ). Rifapentine clearance 
(CL) increased as a result of increased ENZ. V is the apparent volume of distribution. The 
fraction of the drug absorbed (F; relative bioavailability) increased (+) or decreased (-) as 
indicated.  
 
Figure 3. Rifapentine autoinduction profile. (A) The sigmoid relationship between rifapentine 
concentration and autoinduction is shown in the black line. Dashed lines represent the average 
concentration at steady state of daily therapy with 300 mg (yellow), 450 mg (green), and 600 mg 
(navy) of rifapentine in a typical HIV-negative individual. (B) Rifapentine induction over time 
following daily administration of 600 mg. Black dashed line represents the time at which the 
induction process reaches steady state. 
 
Figure 4. Validation of the structural rifapentine population pharmacokinetic model. 
Prediction-corrected visual predictive check (VPC) of base model with (A) analysis dataset, (B) 
validation dataset, and (C) combined dataset. Figures show the model predictions (shaded areas) 
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compared to observed/raw rifapentine concentrations (dots). Model predictions were based on 
the base structural model, built from the analysis dataset alone. The 5th (dashed line), 50th (solid 
line), 95th (dashed line) percentiles of the observed raw data are overlaid onto the 95% 
confidence intervals of model-predicted concentrations at the 50th (light blue), and 5th and 95th 
(dark blue) percentiles, obtained from 500 simulations of each respective dataset. 
 
Figure 5. Relationship between weight and rifapentine clearance. The relationship was 
assessed for (A) all subjects and (B) only DS-TB and LTBI patients with final model parameter 
estimates.  Dashed line represents loess regression curve.  
 
Figure 6. Effect of dose and dosing frequency on rifapentine exposure.  (A) Rifapentine 
concentration over time, and (B) concentration over time in log-scale, in a typical HIV-
uninfected individual following once daily, thrice weekly, twice weekly, and once weekly 
administration of 600 mg (yellow), 900 mg (green), or 1200 mg (dark blue). Black dashed line = 
minimum inhibitory concentration (MIC; equal to 0.06 mg/L) 
 
Figure 7. Pharmacokinetic profiles of rifapentine following (A) 1HP and (B) 3HP regimens.  
Concentration-time profiles over 24 hours are shown for the typical adult by HIV status on (A) 
day 21 of therapy, to reflect steady state concentrations, and (B) after first dose since no 
accumulation occurs with weekly dosing. 
 
Figure 8. Predicted rifapentine exposures with different dosing methods for (A) 1HP and 
(B) 3HP regimens.  Drug exposure over 24 hours (AUC0-24h) profiles are based on 500 
 27 
simulations. (A) 1HP predictions reflect steady state exposures to account for autoinduction. 
‘Weight band’ rifapentine doses were 300 mg for < 35 kg, 450 mg for 35-45 kg, and 600 mg for 
>45 kg, as currently recommended for 1HP. The ‘Flat’ approach prescribed 600 mg to all 
individuals, and ‘HIV stratified’ increased dose in HIV-positive to 750 mg. (B) 3HP doses were 
750 mg for <50 kg and 900 mg for 50+ kg for the ‘weight band’ approach, as currently 
recommended. The ‘Flat’ approach prescribed 900 mg to all individuals, and ‘HIV stratified’ 
increased dose in HIV-positive to 1200 mg. Gray dashed lines represent (B) the median AUC0-24h 
(=317 mg*h/L) observed in patients treated with 3HP in the PREVENT-TB trial (i.e., TBTC-26) 
and (A) the median predicted AUC0-24h in HIV-positive patients with 600 mg daily (=219 
mg*h/L). 
 
Figure 9. Predictors of month 2 culture conversion. Data were acquired from two Phase II 
clinical studies (TBTC29, TBTC29x) where participants received 10 mg/kg rifapentine daily. 
Odds ratios are from univariate analysis.
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Tables 
Table 1. Baseline characteristics of the study participants in the pooled datasets. 
Trial* (Ref) 
Rifapentine 
Regimen 
N Individuals, 
(N samples) 
Age, yr  Weight, kg  
Female 
sex 
HIV-
positive 
Analysis cohort       
06-0050 (19) 
    Phase 1 
    HV 
    PM 
900 mg thrice 
weekly with low fat 
meal 
14, (269) 41 (24-64) 76 (50-97) 3 (21.4) - 
Rifaquin (12) 
   Phase 3 
   DS-TB 
   PM 
900 mg twice 
weekly or 1200 mg 
once weekly with 
high-fat meal 
241, (846) 32 (18-80) 56 (38-78) 88 (36.5) 46 (19.1) 
TBTC-29B (14) 
   Phase 1 
   HV 
   P[Mdz] 
5 - 20 mg/kg once 
daily with low-fat 
meal 
26, (504) 47 (24-60) 82 (60-99) 5 (19.2) - 
TBTC-25 (29) 
   Phase 2 
   DS-TB 
   PH 
600, 900, or 1200 
mg once weekly on 
empty stomach 
35, (357) 44 (18-68) 65 (46-110) 12 (34.3) - 
ACTG-A5311 (21) 
   Phase 1 
   HV 
   P 
10 mg/kg twice 
daily or 15 or 20 
mg/kg once daily 
with low- or high-
fat meal 
44, (1210) 35 (20-59) 82 (60-99) 12 (27.3) - 
Validation cohort       
TBTC-29X (28) 
   Phase 2 
   DS-TB 
   PHZE 
10, 15, or 20 mg/kg 
once daily with 
high-fat meal 
225, (713) 30 (18-70) 55 (40-83) 66 (29.3) 19 (8.4) 
TBTC-26 (30) 
   Phase 3 
   LTBI 
900 mg once 
weekly with food 
77, (77) 40 (19-63) 81 (49-169) 37 (48.1) - 
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   PH 
TBTC-29 (22) 
   Phase 2 
   DS-TB 
   PHZE 
10 mg/kg 5 days 
per week on empty 
stomach 
158, (158) 36 (18-86) 60 (40-101) 46 (29.1) 16 (10.1) 
RioMar (31) 
   Phase 2 
   DS-TB 
   PHMZ 
7.5 mg/kg once 
daily with food 
43, (167) - 58 (45-83) NR - 
Data are expressed as median (range) or number (percentage). 
* A description of each trial is below including study phase, population, and drug regimen. 
Definition of abbreviations:  NR = not recorded; HV= healthy volunteers; DS-TB = drug-sensitive tuberculosis; LTBI = 
latent tuberculosis infection; P = rifapentine; H = isoniazid. M = moxifloxacin; [Mdz] = midazolam, only administered in 
some of the study participants; Z = pyrazinamide; E = ethambutol. 
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Table 2. Final parameter estimates for the rifapentine population pharmacokinetic model. 
 
Parameter 
Population Estimate Inter-individual variability 
Value [%RSE] 95% CI† %CV [%RSE] 95% CI† 
CL/F (L/h) 1.11 [1.92] 0.952 - 1.48 24.3 [9.34] 12.8 - 28.0 
V/F (L) 36.7 [1.99] 28.5 - 40.9 17.6 [17.7] 10.5 - 24.0 
MTT (h) 1.94 [2.97] 1.83 - 2.04 - - 
NN 2.15 [5.44] 1.66 - 2.70 - - 
Bioavailability  100 fixed - 29.8 [10.8] 21.5 - 34.6 
Fixed effects on 
bioavailability‡ 
    
   Dose 0.0167 [5.30] 0.00343 - 0.0287 - - 
   HIV infection  0.729 [6.26] 0.584 - 0.815 - - 
   High-fat meal 1.49 [3.05] 1.37 - 1.64 - - 
   Fasting 0.731 [5.51] 0.546 - 0.776 - - 
kENZ (h-1)*, || 0.00587 [32.1] 0.00291 - 0.0135 - - 
Emax (%)* 73.0 [25.2] 51.0 - 116 - - 
EC50 (mg/L)* 4.27 [39.8] 1.80 - 6.57 - - 
g 10 fixed - - - 
Residual error of 
rifapentine 
0.577 [4.13] 0.573 - 0.699 - - 
CLm/fm (L/h) 3.11 [12.2] 1.89-6.26 40.0 [6.69] 34.2-44.6 
Vm/fm (L) 2.15 [7.07] 1.67-3.15 - - 
fm, dose ** 0.0185 [3.56] 0.0004 -0.0266 - - 
HIV effect on CLm 1.36 [9.85] - - - 
Residual error of 
metabolite 
0.631 [5.59] 0.560-0.695 - - 
* autoinduction parameters were estimated based on the analysis dataset alone. 
† Confidence intervals were based on 926 (out of 1000) successful bootstrap runs for rifapentine model 
and 999 (out of 1000) successful bootstrap runs for metabolite model. 
‡ Fixed effects on bioavailability (F) were relative to HIV-negative individuals taking 300 mg of 
rifapentine with a low-fat meal, where F=1 for each reference condition. Relative bioavailability is 
calculated as: F=Fdose*FHIV*Fhigh-fat*Ffasting, where Fdose is the relative reduction in bioavailability per 100 
mg above 300 mg (equal to 1- estimate*(dose/100 mg), FHIV is the relative bioavailability in HIV-positive 
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  individuals, Fhigh-fat is the relative bioavailability with a high-fat meal (vs. low-fat meal), and Ffasting is the 
relative bioavailability with fasting (vs. low-fat meal). 
|| Translates to an enzyme turnover half-life of 118 hours. 
** Fraction metabolized is a function of dose, where fm= 1- fm,dose*(dose/100 mg). 
Definition of abbreviations: RSE=relative standard error; CI=confidence interval; CV=coefficient of 
variation; CL/F=apparent clearance; V/F=apparent volume of distribution; MTT=mean transit time; 
NN=number of transit compartments; kENZ=enzyme production rate; EC50=concentration where effect is 
50% of maximum; Emax=maximum effect; g =steepness for Emax equation;  CLm/fm =metabolite clearance;  
Vm/fm =metabolite volume of distribution; Fm,dose= dose-dependent reduction in fraction metabolized. 
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Figures 
Figure 1. PRISMA Flow Diagram 
 
 
 
Figure 2. Final rifapentine pharmacokinetic-enzyme model.  
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Figure 3. Rifapentine autoinduction profile.  
 
 
 
Figure 4. Validation of the structural rifapentine population pharmacokinetic model.  
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Figure 5. Relationship between weight and rifapentine clearance. 
  
 
 
 
Figure 6. Effect of dose and dosing frequency on rifapentine exposure. 
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Figure 7. Pharmacokinetic profiles of rifapentine following (A) 1HP and (B) 3HP regimens.  
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Figure 8. Predicted rifapentine exposures with different dosing methods for (A) 1HP and 
(B) 3HP regimens.   
 
 
Figure 9. Predictors of month 2 culture conversion. 
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